Report: GSK to fund venture firm, back start-ups

In Vivo is reporting that GlaxoSmithKline plans to set aside up to $500 million for a new venture fund that will support its internal R&D work as well as fund start-ups created from de-prioritized assets. GSK President of Pharmaceuticals Russell Greig will take control of the fund June 2, according to In Vivo, relying in part on his contacts developed during his days as senior VP of world-wide business development. The GSK Venture Fund will include SR One, which has invested $550 million in 125 companies but has not sought to directly link their investments to Glaxo's work.

- check out the report from In Vivo

Related Articles:
GSK profits drop
GSK shuffles execs in operations overhaul
Consensus: GSK's Witty faces uphill slog

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.